Table 1.
Diastolic trough-to-peak ratios of angiotensin-converting enzyme inhibitors and calcium channel blockers as administered once daily
| Agent (dose) | Average trough-to-peak ratio, % | ||
|---|---|---|---|
| More than 50% | 50% | Less than 50% | |
| Angiotensin-converting enzyme inhibitors | |||
| Perindoprila (2–16 mg) | ~75–100 | ||
| Fosinopril (20 mg) | 64 | ||
| Ramipril (5 and 10 mg) | 50–63 | ||
| Trandolapril (1 and 2 mg) | 50–100 | ||
| Enalapril (5, 10, and 20 mg) | 40–64 | ||
| Benazeprila (20–80 mg) | ~50 | ||
| Quinaprila (10–80 mg) | ~50 | ||
| Lisinopril (10–80 mg) | 30–70 | ||
| Captoprilb (25–100 mg) | 25 | ||
| Cilazapril (2.5 and 5.0 mg) | 10–80 | ||
| Calcium channel blockers | |||
| Amlodipine (5–10 mg) | 50–100 | ||
| Lacidipine (2–6 mg) | 40–100 | ||
| Nifedipine Coat-Core (30 and 60 mg) | 50–69 | ||
| Nifedipine GITS (30 and 60 mg) | 60–94 | ||
| Verapamil slow-release formulations (240 mg) | 45–100 | ||
| Isradipine slow-release formulationsa (5, 10, 15, and 20 mg) | 76–100 | ||
| Diltiazem slow-release formulations (120, 240, 300, 360, and 480 mg) | 20–80 | ||
| Felodipine ERa (2.5, 5, 10, and 20 mg) | ~40–50 | ||
| Nitrendipine (10–20 mg) | 10–80 | ||